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Background: The aim of the present meta-analysis of cohort studies was to focus on monounsaturated fat (MUFA)
and cardiovascular disease, cardiovascular mortality as well as all-cause mortality, and to distinguish between the
different dietary sources of MUFA.
Methods: Literature search was performed using the electronic databases PUBMED, and EMBASE until June 2nd,
2014. Study specific risk ratios and hazard ratios were pooled using a inverse variance random effect model.
Results: Thirty-two cohort studies (42 reports) including 841,211 subjects met the objectives and were included.
The comparison of the top versus bottom third of the distribution of a combination of MUFA (of both plant and
animal origin), olive oil, oleic acid, and MUFA:SFA ratio in each study resulted in a significant risk reduction for:
all-cause mortality (RR: 0.89, 95% CI 0.83, 0.96, p = 0.001; I2 = 64%), cardiovascular mortality (RR: 0.88, 95% CI 0.80,
0.96, p = 0.004; I2 = 50%), cardiovascular events (RR: 0.91, 95% CI 0.86, 0.96, p = 0.001; I2 = 58%), and stroke (RR: 0.83,
95% CI 0.71, 0.97, p = 0.02; I2 = 70%). Following subgroup analyses, significant associations could only be found
between higher intakes of olive oil and reduced risk of all-cause mortality, cardiovascular events, and stroke,
respectively. The MUFA subgroup analyses did not reveal any significant risk reduction.
Conclusion: The results indicate an overall risk reduction of all-cause mortality (11%), cardiovascular mortality (12%),
cardiovascular events (9%), and stroke (17%) when comparing the top versus bottom third of MUFA, olive oil, oleic
acid, and MUFA:SFA ratio. MUFA of mixed animal and vegetable sources per se did not yield any significant effects
on these outcome parameters. However, only olive oil seems to be associated with reduced risk. Further research is
necessary to evaluate specific sources of MUFA (i.e. plant vs. animal) and cardiovascular risk.
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The most common monounsaturated fatty acids (MUFA)
in daily nutrition is oleic acid, followed by palmitoleic acid,
and vaccenic acid. Moreover, oleic acid represents the top-
most MUFA provided in the diet (~90% of all MUFA). No
dietary recommendations for MUFA are given by the
National Institute of Medicine, the United States De-
partment of Agriculture, the European Food and Safety
Authority and the American Diabetes Association. In con-
trast, the Academy of Nutrition and Dietetics as well as
the Canadian Dietetic Association both promote <20%* Correspondence: lukas.schwingshackl@univie.ac.at
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article, unless otherwise stated.MUFA of daily total energy consumption, while the
American Heart Association sets a limit of 20% MUFA in
their respective guidelines [1-3]. One reason for specific
MUFA recommendations might be their potential benefit
in the primary and secondary prevention of cardiovascular
diseases. However, previous meta-analyses of cohort stud-
ies reported inconsistent results of MUFA on coronary
heart disease (CHD). Jakobsen et al. [4] observed that re-
placement of SFA by MUFA marginally increased the risk
of coronary events, whereas no significant effects on cor-
onary death could be observed. These results are in strong
discrepancy with another meta-analysis of cohort studies,
were Mente et al. [5] reported a significant correlation bet-
ween MUFA intake and a decrease in the relative risk fore BioMed Central Ltd. This is an Open Access article distributed under the terms
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Schwingshackl and Hoffmann Lipids in Health and Disease 2014, 13:154 Page 2 of 15
http://www.lipidworld.com/content/13/1/154CHD. Skeaff and Miller [6] did not observe any effects of
MUFA-rich diets on relative risks of CHD events and
CHD death. Likewise, the most recent meta-analysis by
Chowdhury et al. including nine cohort studies found no
significant associations between MUFA intake, circulating
MUFA and risk of CHD [7].
One explanation for these inconclusive data might be
that different sources of MUFA were not taken into
account. Adopting a western diet means that MUFA is
predominantly supplied by foods of animal origin, while
in south European countries, extra virgin olive oil is the
most dominant source of this type of fatty acid [8].
Results of the recently published PREDIMED trial de-
monstrated major cardiovascular benefits of olive oil and
nuts when compared to a low-fat diet [9]. As a major
outcome parameter, the risk of stroke was reduced, an
event which has not been included in the meta-analyses
mentioned above. In addition, a recent cohort study ob-
served a significant association between dietary olive oil,
higher plasma oleic acid and reduced risk of stroke [10].
Extra virgin olive oil is regarded to be the genuine driver
of the Mediterranean diet and was found to be associ-
ated with a 26% reduced risk of all-cause mortality in
the Spanish branch of the EPIC study [11]. The aim of
the present meta-analysis of cohort studies was to focus
on MUFA and CVD (combining CHD and stroke), car-
diovascular mortality, and all-cause mortality, and to dis-




Queries of literature were performed using the electronic
databases PUBMED, and EMBASE (until 2nd June 2014,
respectively) with no restrictions to language, and calendar
date using the following search terms: (“dietary fat” OR
“fatty acids” OR “monounsaturated fat” OR “mufa” OR
“olive oil” OR “oleic acid” OR “mediterranean diet”) AND
(“cardiovascular disease” OR “myocardial infarction” OR
“coronary heart disease” OR “stroke” OR “mortality”) AND
(“incidence” OR “cohort” OR “follow-up” OR “prospective”
OR “risk ratio” OR “hazard ratio” OR “rate ratio”). More-
over, the reference lists from retrieved articles, systematic
reviews, and meta-analyses were checked to search for
further relevant studies. This systematic review was
planned, conducted, and reported in adherence to stan-
dards of quality for reporting meta-analyses [12]. Litera-
ture search was conducted independently by both authors,
with disagreements resolved by consensus.
Eligibility criteria
Studies were included in the meta-analysis if they met
all of the following criteria: (i) cohort study design; (ii)
data related to dietary consumption of MUFA, MUFA:SFA ratio, olive oil, and oleic acid; (iii) the primary out-
comes were: all-cause mortality, CVD mortality, combined
CVD events (cardiovascular mortality, cardiovascular
morbidity (non-fatal myocardial infarction, angina, stroke,
heart failure, peripheral vascular events)); the secondary
outcomes were: coronary heart disease, and stroke; (iv) ad-
justed relative risks (RRs), and hazard ratios (HRs) with
corresponding 95% confidence intervals (95% CIs) or the
data necessary to calculate these; (v) when a study ap-
peared to have been published in duplicate, the version
containing the most comprehensive information was
selected.
Data extraction and quality assessment
The following data were extracted from each study: the
first author’s last name, year of publication, study origin,
outcome parameter, sample size, study length, age at
entry, sex, specification of MUFA, adjustment factors,
quality score, and risk estimates (HR, RR; highest vs.
lowest category) with their corresponding 95% CIs. If se-
parate risk estimates for males and females or separate
risk estimates for ages were available in one study, the data
were pooled and treated as one study. When a study pro-
vided several risk estimates, the maximally adjusted model
was chosen. To assess the study quality, a 9-point scoring
system according to the Newcastle-Ottawa Scale (NOS)
was used. Hence, the full score was 9, and a high-quality
study in the present analysis was defined by a threshold
of ≥ 7 points [13]. Data extraction and quality assessment
were performed by one author (L.S).
Statistical analysis
The meta-analysis was performed by combining the
multivariable adjusted RR or HR of the highest com-
pared with the lowest MUFA, MUFA:SFA ratio, oleic
acid, or olive oil category based on random effects model
using DerSimonian-Laird method, which incorporated
both within and between study variability [14]. To en-
sure a transparent approach to meta-analysis and inter-
pretation of findings in this review, RR/HR estimates
for association of fatty acids and primary/secondary out-
comes that were often differently reported by each study
(such as per-unit or per-1-SD change or comparing
quintiles, quartiles, thirds, and other groupings) were
transformed, using methods previously described [7].
These transformed estimates consistently corresponded
to the comparison of the top versus bottom third of
MUFA, MUFA:SFA ratio, olive oil, and oleic acid distri-
bution in each study. To evaluate the weighting of each
study, the standard error for the logarithm HR/RR of
each study was calculated and regarded as the estimated
variance of the logarithm HR/RR using an inverse va-
riance method [14]. Studies were grouped according to
the different clinical outcomes (all-cause mortality,
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coronary heart disease, and stroke). Subgroup analysis was
performed for total MUFA, MUFA:SFA ratio, oleic acid,
and olive oil. Heterogeneity was estimated by the
Cochrane Q test together with the I2 statistic. An I2 value
>50% indicates substantial heterogeneity across studies
[15]. The heterogi command in STATA was used to
calculate the confidence intervals for the heterogeneity
estimates. Funnel plots were used to assess potential pub-
lication bias. To determine the presence of publication
bias, we assessed the symmetry of the funnel plots in
which mean differences were plotted against their cor-
responding standard errors. In addition, Egger test was
performed to test for potential publication bias [16]. Sensi-
tivity analyses were performed assuming statistical hete-
rogeneity with the metaan command in STATA [17]. All
analyses were conducted using the Review Manager by
the Cochrane Collaboration (version 5.2) and STATA 13.0
(Stata-Corp, College Station, TX).
Missing data
Dr. Goldbourt (personal communication) provided the
23 year follow-up all-cause mortality and cardiovascular
mortality data of the Israeli civil cohort for the highest
vs. lowest quintile MUFA: SFA ratio [18].
Results
Literature search and study characteristics
A total of 32 cohort studies (42 reports) met the inclu-
sion criteria and were included in the meta-analysis
[10,11,18-57]. Full search strategy for PUBMED is given
in the Additional file 1. General study characteristics are
given in Table 1. Sample size varied between 161 and
161,808 with a follow-up time ranging from 3.7 to
30 years. The total number of subjects in the included
studies was 841,211.
Main outcomes
According to the different clinical outcomes, overall risk
of all-cause mortality was evaluated in seventeen cohorts,
cardiovascular mortality in fourteen cohorts, combined
cardiovascular events in twenty-eight cohort studies, cor-
onary heart disease in fifteen cohorts, and stroke in eleven
cohorts, respectively.
Random effects model data (as summarized in Table 2)
revealed that top versus bottom third combined MUFA,
olive oil, oleic acid, and MUFA:SFA ratio was significantly
associated with a reduced risk of: all-cause mortality (rela-
tive risk, RR: 0.89, 95% confidence interval 0.83 to 0.96;
p = 0.001, I2 = 64%) (Figure 1), cardiovascular mortality
(RR: 0.88, 95% CI 0.80 to 0.96, p = 0.004, I2 = 50%)
(Figure 2), combined cardiovascular events (RR: 0.91, 95%
CI 0.86 to 0.96, p = 0.001, I2 = 58%) (Figure 3), and stroke
(RR: 0.83, 95% CI 0.71 to 0.97, p = 0.02, I2 = 70%). Incontrast, no significant changes could be observed for
coronary heart disease (RR: 0.96, 95% CI 0.90 to 1.01,
p = 0.13, I2 = 41%).
Subgroup/sensitivity analyses
Following subgroup analyses, olive oil most likely turned
out to be crucial for the results of the primary analysis,
since significant associations could only be found between
higher intakes of olive oil and reduced risk of all-cause
mortality (RR: 0.77, 95% CI 0.71 to 0.84, p < 0.00001,
I2 = 0%), cardiovascular events (RR: 0.72, 95% CI 0.57 to
0.91, p = 0.007, I2 = 77%), and stroke (RR: 0.60, 95% CI
0.47 to 0.77, p < 0.0001, I2 = 0%), respectively. Subgroup
analysis for MUFA (of mixed animal and plant origin) did
not reveal any significant risk reduction for all-cause mor-
tality (RR: 1.00, 95% CI 0.93 to 1.08, p = 0.93, I2 = 23%),
cardiovascular mortality (RR: 0.95, 95% CI 0.89 to 1.02,
p = 0.14, I2 = 52%), cardiovascular events (RR: 0.96, 95%
CI 0.89 to 1.04, p = 0.36, I2 = 7%), coronary heart disease
(RR: 0.99, 95% CI 0.93 to 1.06, p = 0.76, I2 = 29%), and
stroke (RR: 0.85, 95% CI 0.72 to 1.01, p = 0.07, I2 = 65%).
To investigate statistical heterogeneity, sensitivity analyses
were performed with the metaan command in STATA.
Heterogeneity of the main analysis could be confirmed in
the sensitivity analyses. Differentiating between studies
performed in Europe vs. non-European investigations re-
sulted in significant differences as compared to the main
analysis. Pooling European based cohorts resulted in a sig-
nificant risk reduction for all-cause mortality (RR: 0.87,
95% CI 0.79 to 0.95) as well as for cardiovascular mortality
(RR: 0.76, 95% CI 0.64 to 0.91) and cardiovascular events
(RR: 0.86, 95% CI 0.78, 0.95). In contrast, no significant
reduction in all-cause mortality risk (RR: 0.97, 95% CI
0.91 to 1.04) could be observed for non-European cohorts
(the respective data for cardiovascular mortality being
RR: 0.94, 95% CI 0.89 to 0.99 and for cardiovascular
events being RR: 0.93, 95% CI 0.87 to 0.98). With respect
to study length, studies with a follow-up ≥ 10 years re-
sulted in similar results as compared to short-term studies
(<10 years follow up). Likewise, high quality studies could
confirm the results of the primary analysis.
Publication bias
The Egger’s linear regression tests provided evidence for
a potential publication bias for combined cardiovascular
events (p = 0.018), all-cause mortality (p = 0.041), and
cardiovascular mortality (p = 0.12) following comparison
of the top versus bottom third combined MUFA, olive
oil, oleic acid, and MUFA:SFA ratio. No evidence of pub-
lication bias could be detected for risk of CHD (p = 0.28)
and stroke (p = 0.28). All funnel plots indicate little to
moderate asymmetry, suggesting that publication bias
cannot be completely excluded as a factor of influence on
the present meta-analysis (Additional file 1: Figures S1,
Table 1 General study characteristics of the included cohort studies





















3,328 11.3 60-79 M Olive oil Age, energy intake, smoking, alcohol, PA,
social class, BMI, and a modified version of
the HDI/EDI score not containing the















6.5 59 M/F Olive oil Age, sex, hypertension, HDL-cholesterol,
diabetes, smoking, claudication, electrical
instability, left ventricular dysfunction,











CHD 29,689 7.85 35-74 F MUFA MUFA:SFA Energy intake, educational level, smoking
status, alcohol consumption, body height,
body weight, waist circumference daily
non-alcohol caloric intake, hypertension,
















41,078 10.4 29-69 M/F Olive oil Centre, sex, age, energy intake, BMI, waist
circumference, educational status, smoking
status, PA, and alcohol intake, intake of fruit,










CHD 40,142 10.4 29-69 M/F Olive oil Educational level, BMI, waist circumference,
PA, smoking status, alcohol consumption,
energy intake excluding alcohol,
hyperlipidaemia, hypertension and diabetes,









Sudden death 91,981 30 34-59 F MUFA Total calories, smoking, BMI, family history of
myocardial infarction, menopausal status,
hormone therapy, exercise, aspirin use, use
of multivitamins, use of vitamin E
supplements, alcohol use, and history of
diabetes, hypertension,
hypercholesterolemia, coronary heart
disease, and cancer at baseline, percentage













23,929 10 20-86 M/F MUFA Olive Oil
MUFA:SFA
Age, BMI, height, PA, years of schooling and
energy intake entered, alcohol consumption,









CVD mortality 4,546 12.4 ≥30 M/F MUFA Age, sex, energy intake, serum lipids, systolic
blood pressure, cigarette smoking, BMI,
glucose intolerance




































2,568 9 >40 M/F MUFA:SFA Age, sex, race ethnicity, completion of high
school education, moderate-to-heavy PA,








Stroke 832 20 45-65 M MUFA Age, energy, systolic blood pressure,
cigarette smoking, glucose intolerance, BMI,
























7216 4.8 55-80 M/W Olive oil Age, sex, BMI, smoking status, alcohol intake,
education level, PA, prevalence of diabetes,
prevalence of hypertension, prevalence
of hypercholesterolemia, use of










Stroke 43,732 14 40-75 M MUFA BMI, PA, history of hypertension, smoking
status, aspirin use, multivitamin use, and
consumption of alcohol, potassium, fibre,
and vitamin E, total servings of fruit and









CVD events 1,941 9 70-79 M/F MUFA Age, gender, race, education, field centre,
smoking, alcohol use, PA, BMI, total energy
intake, protein intake, fibre intake,
multivitamin use, supplemental vitamin E
use, statin use, aspirin use, oral estrogen use,
and prevalent diabetes or hypertension, fat,








Stroke 85,764 14 30-59 F MUFA Age, smoking status, time interval, BMI,
alcohol intake, menopausal status and
postmenopausal hormone use, vigorous
exercise, usual aspirin use, multivitamin
use, vitamin E use, n-3 fatty acid intake,
calcium intake, and histories of hypertension,







JAP Stroke 4,775 14 40-69 M/F MUFA Age, sex, quartiles of total energy intake and
BMI, hypertension category, diabetes, serum
total cholesterol, smoking status, ethanol



































disease I, II EU
CHD 3,686 16 30-71 M/F MUFA Total energy intake, energy from protein,
energy from fat, energy from carbohydrates,




et al. 1999 [55]
AUS All-cause
mortality










Stroke 34,670 10.4 49-83 F MUFA Age, smoking status and pack-years of
smoking, education, BMI, PA, history of
hypertension, history of diabetes, aspirin use,
family history of myocardial infarction,









161 9 65-95 M/F MUFA:SFA Age, sex, BMI, albumin concentration, PA,














28,098 13.5 44-73 M/F MUFA MUFA:SFA Age, smoking habits, alcohol consumption,
socioeconomic status, marital status, PA,
BMI, fibre intake, and blood pressure, total
















4.6 50-79 F MUFA:SFA Age at heart failure hospitalization, total
energy intake, race/ethnicity, education,
income, married, current smoking, total
exercise, physical function, use of off-study
postmenopausal hormone therapy,
Women’s Health Initiative (WHI) study arm,
systolic blood pressure, diastolic blood
pressure, use of diuretics, β-blockers, and
angiotensin converting enzyme inhibitors or
angiotensin receptor blockers, BMI, and
history of high cholesterol, high blood
pressure, diabetes mellitus, myocardial
















M/F MUFA:SFA Age, years of university of education, BMI,
smoking, PA, hours per day spent watching
television, history of depression, baseline
hypertension, baseline hypercholesterolemia,
total energy intake, egg consumption,











CVD CHD 13,609 4.9 University
graduates
(mean: 38)
M/F MUFA:SFA Age, sex, family history of coronary heart
disease, total energy intake, PA, smoking,
BMI, diabetes at baseline, use of aspirin,









































23,601 10.6 20-87 M/F MUFA Olive Oil Age, sex, education, smoking status, BMI, PA,















28,356 16 ≥35 M/F MUFA Age, non-alcohol energy, and protein
expressed as percentage of non-alcohol
energy and was additionally adjusted for fat
subtypes expressed as percentage of
non-alcohol energy as appropriate, height,
BMI, PA, smoking status, alcohol intake,
education, marital status, menopausal status,
histories of diabetes and hypertension, and








CHD 78,778 20 30-55 F MUFA Age, BMI, smoking, alcohol intake, parental
history of myocardial infarction, history of
hypertension, menopausal status and
hormone use, aspirin use, multivitamin use,
vitamin E supplement use, PA, energy,
protein, cholesterol intake, saturated,
polyunsaturated, and trans-fat; a-linolenic













21,930 6.1 50-69 M MUFA Oleic acid Age, smoking, BMI, blood pressure, energy








CHD 813 16 45-65 M MUFA Energy, serum cholesterol levels, PA, systolic
blood pressure, left ventricular hypertrophy,









JAP Stroke 3,731 14 35-89 M/F MUFA Age, sex, adjusted for radiation dose, city,
BMI, smoking status, alcohol habits, and









Stroke 7,625 5.25 ≥65 M/F Olive oil Age, sex, education, smoking status, BMI, PA,













278 8.5 65-84 F MUFA MUFA:SFA Age, sex, waist-hip ratio, smoking status,









1,037 8.5 70 M/F MUFA:SFA Gender, BMI, waist circumference, PA,



























Table 1 General study characteristics of the included cohort studies (Continued)
Trichopoulou








74,607 7.4 >60 M/F MUFA MUFA:SFA Age, sex, diabetes mellitus at baseline, waist
to hip ratio, BMI, educational achievement,
smoking status, PA at occupation, PA score














23,349 8.5 20-86 M/F MUFA:SFA Age, sex, education, smoking status,






et al. 1995 [22]
GRE All-cause
mortality











22,043 3.7 20-86 M/F MUFA Olive oil
MUFA:SFA
Age, sex, waist-to-hip ratio, energy-
expenditure score, years of education,
smoking status, BMI, and total energy intake
MUFA (15 g/d)
Increment











120,852 10 55-69 M/F MUFA:SFA Age, cigarette smoking status, number of
cigarettes smoked per day, years of
smoking, BMI, non-occupational PA, history











Stroke 87,025 7.6 50-79 F MUFA Age, race, education, family income, total
metabolic equivalent task hours per week,
alcohol intake, history of CHD, history of
atrial fibrillation, history of diabetes, aspirin
use, use of antihypertensive medication, use
of cholesterol-lowering medication, BMI,
systolic blood pressure, and total energy











2,938 7.2 47-79 M/F MUFA Age, sex, energy, study centre, diabetes
status, BMI, HDL, LDL, triacylglycerol,
smoking, alcohol consumption,
hypertension, percentage of energy from












58,672 19.3 40-79 M/F MUFA Age, area, education, smoking, alcohol
consumption, BMI, sleep duration, walking,





BMI Body Mass Index, CHD coronary heart disease, CVD cardiovascular disease, DEN Denmark, EDI Elderly Diet Index, EU European Union, FRA France, GBR Great Britain, HDI Healthy Diet Index, ISR Israel, ITA Italy, JAP

























Table 2 Relative risk for all-cause mortality, cardiovascular mortality, combined cardiovascular events, stroke, and
coronary heart disease (with 95% confidence intervals) comparing the top versus bottom third of MUFA, MUFA:SFA
ratio, olive oil, and oleic acid
Outcome No studies MUFA source Relative risk 95% CI p-value I2 (%)a 95% CI
All-cause mortality 17 All MUFA combined 0.89 0.83 to 0.96 0.001 64
42 to 78
5 MUFA 1.00 0.93 to 1.08 0.93 23
10 MUFA:SFA 0.90 0.82 to 1.00 0.04 59
5 Olive oil 0.77 0.71 to 0.84 <0.00001 0
Cardiovascular mortality 14 All MUFA combined 0.88 0.80 to 0.96 0.004 50
15 to 71
8 MUFA 0.96 0.89 to 1.04 0.36 7
4 MUFA:SFA 0.91 0.83 to 0.99 0.04 0
5 Olive oil 0.70 0.48 to 1.03 0.07 71
1 Oleic acid 0.81 0.66 to 0.99 0.04 n.a.
Combined cardiovascular events 30 All MUFA combined 0.91 0.86 to 0.96 0.001 58
38 to 71
20 MUFA 0.95 0.89 to 1.02 0.14 52
6 MUFA:SFA 0.93 0.86 to 1.01 0.07 0
7 Olive oil 0.72 0.57 to 0.91 0.007 75
1 Oleic acid 0.87 0.76 to 1.00 0.04 n.a.
Stroke 11 All MUFA combined 0.83 0.71 to 0.97 0.02 70
46 to 84
9 MUFA 0.85 0.72 to 1.01 0.07 65
1 MUFA:SFA 1.18 0.91 to 1.53 0.21 n.a.
2 Olive oil 0.60 0.47 to 0.77 <0.0001 0
Coronary heart disease 15 All MUFA combined 0.96 0.90 to 1.01 0.13 41
0 to 66
9 MUFA 0.99 0.93 to 1.06 0.76 29
4 MUFA:SFA 0.94 0.86 to 1.02 0.14 0
4 Olive oil 0.80 0.57 to 1.14 0.22 77
1 Oleic acid 0.87 0.76 to 1.00 0.04 n.a.
aI2 inconsistency, percentage of variation across studies due to heterogeneity.
MUFA monounsaturated fatty acids, n.a. not applicable, SFA saturated fatty acids.
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with inconclusive results have not been published or failed
to do so.
Discussion
In the present meta-analysis, comparison of the top ver-
sus the bottom third of combined MUFA subgroups
(MUFA, olive oil, oleic acid, and MUFA:SFA) was asso-
ciated with reduced risk of all-cause mortality (11%),
cardiovascular mortality (12%), combined cardiovascular
events (9%), and stroke (17%). In the ensuing subgroup
analyses, this significant correlation could only be ob-
served between higher intakes of olive oil and reduced
risk of all-cause mortality, cardiovascular events, and
stroke, respectively. In contrast, monounsaturated fattyacids of mixed animal and plant origin did not result in
any significant effects with respect to these outcome pa-
rameters. Thus, it seems possible that olive oil repre-
sents the crucial factor of influence for the protective
health effects observed in the primary analysis. However,
one has to keep in mind the limitations of the present
systematic review and meta-analysis summarized at the
end of this section, especially the fact that the specific
sources of MUFA have not been indicated in every
study.
In order to properly evaluate the potential beneficial
or detrimental effects of MUFA with respect to cardio-
vascular diseases, it seems of importance to consider the
source of food providing these fatty acids. In the Nurses’
Health Study, MUFA intake was highly correlated with
Figure 1 Forest plot showing pooled relative risks (RRs) with 95% CI for all-cause mortality comparing the top versus bottom third of
the distribution of MUFA, MUFA:SFA ratio, olive oil, and oleic acid. I2: Inconsistency; MUFA: monounsaturated fatty acids; SE: standard error;
SFA: saturated fatty acids.
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erately correlated with intakes of PUFA (correlation coeffi-
cient of 0.30), suggesting that fat was primarily of animal
origin [58]. In the different EPIC cohorts, MUFA intakes
ranged between approximately 10% of daily total energy
consumption (TEC) in The Netherlands and ~ 20% of
TEC in Greece. In general, intake of MUFA was higher in
southern European countries as compared central or
northern cohorts. However, another distinguishing feature
seems to be the predominant source of MUFA in the re-
spective cohorts. In Greece, Spain, and Italy, fat of plant
origin (mainly olive oil) provided up to 64% of MUFA
intake, whereas in most other EPIC centers, the main con-
tributors to total MUFA intake were meat and meat pro-
ducts, added fats, and dairy products [8]. This might also
provide an explanation for the somewhat mixed results
provided by systematic reviews and meta-analyses in the
past. Thus, a diet rich in MUFA was found to have benefi-
cial effects on a broad range of CVD risk factors, not only
in the primary prevention of CVD [1,59-61]. On the other
hand, no association between total and individual MUFA
and CHD was reported in a meta-analysis of studiesassessing both dietary intake and circulating fatty acid
composition, [7] while a meta-analysis of observational
studies suggested that replacing SFAs with PUFAs might
have a greater benefit than replacement of SFAs by MUFA
[4]. There is some evidence drawn from prospective stu-
dies of an adverse association between MUFA and coron-
ary events, but this correlation might be influenced by
high amounts of MUFA of animal origin [4].
A number of in-vivo and in-vitro studies examined the
health effects of extra virgin olive oil, the potential
“Unique Selling Proposition” of a genuine Mediterranean
diet. Thus, the Di@bet.es study demonstrated that indi-
viduals who consumed olive oil had a significantly lower
risk of developing obesity, impaired glucose metabolism,
hypertriglyceridemia, and lower HDL cholesterol levels
as compared to a group consuming sunflower oil [62].
In addition, results from experimental studies provide
evidence that olive oil consumption improves several
CHD risk factors [63,64]. The PREDIMED dietary inter-
vention trial aimed a intake of 50 g/d or more of extra
virgin olive oil observed a significant risk reduction of
both combined cardiovascular events as well as primary
Figure 2 Forest plot showing pooled relative risks (RRs) with 95% CI for cardiovascular mortality comparing the top versus bottom
third of the distribution of MUFA, MUFA:SFA ratio, olive oil, and oleic acid. I2: Inconsistency; MUFA: monounsaturated fatty acids;
SE: standard error; SFA: saturated fatty acids.
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the results of the present meta-analyses of cohort studies
[9]. In a long-term intervention trial by Esposito et al., a
higher regression in as well as a lower rate of progres-
sion of the intima–media thickness of the carotid artery
was found in the group adopting a Mediterranean diet
as compared to a low-fat diet reference arm [65].
Apart from oleic acid, olive oil contains a number of
bioactive compounds such as polyphenols which are
especially prominent in virgin and extra-virgin olive oil,
but not in refined olive oil [64,66]. A key olive oil poly-
phenol is oleuropein (a compound that generates tyrosol
and hydroxytyrosol), which accounts for approximately
80% of olive oil phenolic content and is a potent scaven-
ger of superoxide radicals and inhibits LDL oxidation
[67,68]. There is a causal link between oxidative stress,
inflammation, endothelial dysfunction, and CVD/CHD
[69]. A meta-analysis of intervention trials provide evi-
dence that an MD decreases inflammation and improves
endothelial function [70]. When focusing on virgin oliveoil consumption, the inverse correlation between olive
oil and CHD risk found in the present meta-analysis is
consistent with the fact that olive oil is not just a sup-
plier of MUFA but of other biologically active compo-
nents as well.
Several limitations should be taken into account when
interpreting the results of the present meta-analysis.
MUFA coexist with SFA in several food sources. In
addition, cis- and trans-isomers of MUFAs were some-
times categorized together in cohort studies. Furthermore,
moderate to substantial heterogeneity could be observed
in the present meta-analysis. Potential sources of hetero-
geneity include combining MUFA/olive oil/oleic acid/
MUFA:SFA ratio in the same analysis, heterogeneous risk
estimates, heterogeneous populations/ages/gender, sample
sizes as well as follow-up periods of the included studies.
No unpublished data were considered for the present
meta-analysis, and it cannot be excluded that these results
may influence the effect size estimates. Examination
of funnel plots showed little to moderate asymmetry
Figure 3 Forest plot showing pooled relative risks (RRs) with 95% CI for combined cardiovascular events comparing the top versus
bottom third of the distribution of MUFA, MUFA:SFA ratio, olive oil, and oleic acid. I2: Inconsistency; MUFA: monounsaturated fatty acids;
SE: standard error; SFA: saturated fatty acids.
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http://www.lipidworld.com/content/13/1/154suggesting that publication bias cannot be completely ex-
cluded as a confounder of the present meta-analysis (e.g.
it remains possible that small studies yielding inconclusive
data have not been published). In addition, the specific
food sources of MUFA could not always identified, limi-
ting the validity of any general recommendation towards
MUFAs of plant origin (it is most likely olive oil, but it
might be other types of food as well, e.g. nuts, canola oil
or a specific variety of sunflower oil). Conversely, it mightbe that results from studies using mixed sources of
MUFA might be biased by non-identified olive oil,
making MUFA appear to be beneficial in general when
some sources are not. Furthermore, observational stud-
ies including cohort studies assessing outcome events
affected by nutrition should be interpreted with caution,
since reliance on nutritional assessment methods with
validity and reliability is lower when compared to ran-
domized controlled trials.
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strengths as well. Compared to cohort studies, dietary
intervention trials are often limited by lack of double
blinding, non-compliance, cross-over, and high drop-out
rates. Therefore, well-designed analyses in prospective
cohort studies could also provide important evidence
with respect to long-term clinical outcomes. Another
strength of this work is the inclusion of an overall popu-
lation >800,000 subjects. To the best of our knowledge,
this represents the most comprehensive summary of the
evidence on MUFA, olive oil, MUFA:SFA on hard cli-
nical outcome parameters.
Conclusion
The results of the present meta-analysis indicate an overall
risk reduction of all-cause mortality (11%), cardiovascular
mortality (12%), cardiovascular events (9%), and stroke
(17%) when comparing the top vs. bottom thirds of a
combination of MUFA, olive oil, oleic acid, and MUFA:
SFA ratio. Monounsaturated fat of mixed animal and
vegetable sources per se did not yield any significant ef-
fects on these outcome parameters. Subgroup analysis in-
dicated that only olive oil (the primary monounsaturated
fat source in south European countries) is was associated
with a significant risk reduction for several outcomes.
These data provide evidence that the source and origin of
MUFA within a specific diet should be taken into account
in order to evaluate the potential benefits of this type of
fatty acids. Further studies are required evaluating specific
food sources of MUFA and risk of all-cause mortality and
CVD events.
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